Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700022221

Next Previous
X
Search
Trial Profile

Clinical Trials Insight: 700022221

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2010

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ulipristal (Primary)
  • Indications Pregnancy
  • Focus Registrational; Therapeutic Use
  • Sponsors HRA Pharma

    • Most Recent Events

    • 13 Aug 2010 According to a company media release, Watson Pharmaceuticals plans to launch Ella [ulipristal] as an emergency contraceptive in the fourth quater of 2010.
    • 13 Aug 2010 According to an HRA Pharma media release, the US FDA has granted approval for ulipristal as a prescription-only emergency contraceptive, based on results of this and another phase III trial (CTP 700019630).
    • 04 Apr 2007 The expected completion date for this trial is now 31 Dec 2007.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top